Springer Nature
Browse
12885_2015_1685_MOESM2_ESM.docx (16.88 kB)

Additional file 2: of Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Download (16.88 kB)
journal contribution
posted on 2015-10-14, 05:00 authored by Hitoshi Soda, Hiromichi Maeda, Junichi Hasegawa, Takao Takahashi, Shoichi Hazama, Mutsumi Fukunaga, Emiko Kono, Masahito Kotaka, Junichi Sakamoto, Naoki Nagata, Koji Oba, Hideyuki Mishima
Adverse events in patients treated with cetuximab and oxaliplatin-based chemotherapy. (DOCX 16 kb)

History

Usage metrics

    BMC Cancer

    Categories

    Keywords

    FOLFOXAdditionalFLEET studywild-typeoxaliplatin-based chemotherapycetuximabcolorectalXELOXmetastaticKRASMulticenter Phase II studyDOCX 16  kbfirst-line therapyErbitux

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC